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Abstract. Purpose: Gastrointestinal stromal tumours
(GIST) are mesenchymal neoplasms of the gastrointesti-
nal tract that are unresponsive to standard sarcoma che-
motherapy. Imaging of GIST patients is done with struc-
tural and functional methods such as contrast-enhanced
helical computed tomography (ceCT) and positron emis-
sion tomography (PET) with 18F-fluorodeoxyglucose
(FDG). The aim of this study was to compare the prog-
nostic power of PET and ceCT and to evaluate the clini-
cal role of PET/CT imaging. Methods: All patients with
GIST undergoing PET or PET/CT examinations were
prospectively included in this study, and the median
overall survival, time to progression and treatment dura-
tion were documented. The prognostic significance of
PET and ceCT criteria of treatment response was as-
sessed and PET/CT was compared with PET and ceCT
imaging. Data for 34 patients (19 male, 15 female, 21–
76 years) undergoing PET or PET/CT for staging or
restaging were analysed. Results: In 28 patients, PET/CT
and ceCT were available after introduction of treatment
with the tyrosine kinase inhibitor imatinib mesylate
(Gleevec; Novartis, Basel, Switzerland). Patients without
FDG uptake after the start of treatment had a better 
prognosis than patients with residual activity. In contrast,
ceCT criteria provided insufficient prognostic power.
However, more lesions were found on ceCT images 
than on PET images, and FDG uptake was sometimes
very variable. PET/CT delineated active lesions better
than did the combination of PET and ceCT imaging.
Conclusion: Both PET and PET/CT provide important
prognostic information and have an impact on clinical
decision-making in GIST patients. PET/CT precisely 
delineates lesions and thus allows for the correct plan-
ning of surgical interventions.
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Introduction
Gastrointestinal stromal tumours (GIST) are mesenchy-
mal tumours that in approximately 90% of cases originate
in the stomach and small intestine [1]. They have a wide
clinical spectrum ranging from benign incidentally de-
tected nodules to large malignant tumours and must be
distinguished from other mesenchymal tumours [2].
There is a range of histological variants. GIST are de-
fined as KIT-positive tumours because they have a com-
mon molecular pathogenesis with activating mutations in
the gene encoding KIT (CD117, stem cell factor receptor)
and positivity of cKIT on immunohistochemistry is a
conditio sine qua non for the diagnosis of GIST [2]. Co-
expression of KIT with CD34 can often be found since
both originate from a CD34-positive subset of Cajal cells,
the pacemaker cells of the gastrointestinal tract [2, 3].
The only curative therapy for localised GIST is sur-
gery. Tumours are usually resistant to conventional cyto-
toxic chemotherapy and radiation [4]. Recently a target-
ed therapy with imatinib mesylate (also referred to as
STI-571, Gleevec or Glivec; Novartis, Basel, Switzer-
land), a receptor tyrosine kinase inhibitor, has been intro-
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duced for the treatment of GIST. This substance inhibits
the activated KIT protein located on the tumour cell
membrane [5].
Structural imaging with contrast-enhanced helical
computed tomography (ceCT) is widely used to assess
therapy response in GIST patients [6]. It has previously
been shown that GIST tumours treated with imatinib me-
sylate may not change their size or may even grow larger
during therapy [7]. However, the assessment of tumours
responding to treatment with imatinib mesylate may
show a decrease in CT attenuation values (Hounsfield
units, HU) [7]. A delay of several weeks to months can
be observed between the functional changes at a cellular
level that are induced by an effective treatment and the
macroscopic structural changes in a tumour as measured
by ceCT [8]. In contrast, positron emission tomography
(PET) using 18F-fluorodeoxyglucose (FDG), a glucose
analogue which is taken up into cells without being fur-
ther metabolised, is able to show early effects in patients
undergoing treatment with imatinib mesylate [8, 9]. Ad-
ditionally, recent studies have suggested that a decrease
in FDG uptake after the start of imatinib mesylate treat-
ment indicates a positive treatment result and a pro-
longed progression-free survival [8, 10].
The first aim of this study was to compare the prog-
nostic value of early PET imaging after introduction of
imatinib mesylate treatment with the prognostic value of
ceCT imaging. We correlated imaging response with time
to progression and overall survival. Secondly, the find-
ings of PET imaging were compared with those of ceCT
and the results of in-line PET/CT were compared with the
combined reading of PET and ceCT images in order to
assess the additional value of PET and PET/CT imaging.
Materials and methods
Patients
Consecutive patients with histologically proven CD117-positive
GIST undergoing PET and PET/CT examinations in our institution
were analysed. All patients were treated with imatinib mesylate.
The patients were followed prospectively with clinical examina-
tions and radiological imaging every 3 months. Patients received
either a 400- or an 800-mg starting dose of imatinib mesylate per
os daily. In the event of progression at 400 mg, the dose was in-
creased to 800 mg/day. In cases of toxicity, the doses were reduced.
The local ethics committee approved the protocol and all patients
gave informed written consent for participation in the study.
Imaging
PET imaging was performed on an Advance and a Discovery LS
camera (both GE Medical Systems, Waukesha, WI). In the Dis-
covery LS, an Advance NXi PET camera and a multislice helical
CT scanner (LightSpeed plus) are integrated to allow the acquisi-
tion of automatically aligned CT and PET images in one session.
Patients fasted for at least 4 h prior to scanning, which was started
approximately 45 min after the injection of a standard dose of 
approximately 370 MBq of FDG. The supine patients were 
examined if possible with the arms above the head. First, the CT
scan was acquired starting at the level of the head and using the
following parameters: 80-mA tube current, 0.5 s per tube rotation,
140-kV tube voltage, slice thickness of 5 mm with four simultane-
ous slice acquisitions and a helical pitch of approximately six over
a 867-mm scan length covering the body from the head to the pel-
vic floor. This whole-body CT scan was acquired in 22.5 s and in
a breath-hold respiration position to avoid artefacts due to erro-
neous image co-registration and attenuation correction [11]. In all
patients, oral contrast medium was given for 1 h starting approxi-
mately 60 min before scanning to improve the delineation of intes-
tinal organs [12]. However, the CT scan was done without intrave-
nous contrast enhancement, because all patients had already un-
dergone ceCT as part of their routine work-up. Immediately fol-
lowing the CT acquisition, the PET emission scan was acquired
starting at the pelvic floor. In both scanners the PET camera has a
14.6-cm axial field of view and a transaxial resolution of 4.8 mm
full-width at half-maximum at the centre. The PET scans were 
obtained using an acquisition time of 4 min for the emission data.
On the combined PET/CT scanner the CT data were used for at-
tenuation correction, thus reducing the examination time to ap-
proximately 25 min. On the Advance PET camera a conventional
transmission scan of 2 min per cradle position, with a one-slice
overlap at the borders of the field of view, was acquired. In con-
trast, scanning a patient using six table positions covering the
body from the pelvic floor to the head resulted in an acquisition
time of roughly 36 min. During image acquisition the patients
were under supervision by a technician. The PET data were recon-
structed using a standard iterative algorithm (OSEM, 28 subsets, 
2 iterative steps). The decision on whether to perform PET or inte-
grated PET/CT depended on the availability of the scanner, except
in a subgroup of patients who underwent PET/CT scanning before
and after the introduction of imatinib mesylate treatment.
In these patients the helical ceCT was acquired in the universi-
ty hospital of Lausanne using a LightSpeed Ultra eight-detector
CT (General Electric Medical Systems, Waukesha, WI). Helical
CT was obtained with section collimation of 5 mm with a pitch of
1.675:0.8. Scanning of the chest and abdomen was performed after
initiation of contrast infusion, at 25 s for thorax and at 60 s for ab-
domen. Oral administration of water or contrast (2%) was given
20 min before examination and contrast enema (2%) was given
immediately before examination. The contrast enhancement was
obtained with 80 ml of iodinated material (Accupaque 300) inject-
ed with a mechanical power injector at a rate of 2.7 ml/s.
Image analysis
The acquired images were viewed with software providing multi-
planar reformatted images of PET, CT and fused data with linked
cursors (eNtegra GE Medical Systems, Haifa, Israel). PET and CT
images were displayed using black and white images. The co-reg-
istered PET/CT scans were displayed using a standard grey scale
for the CT images and a colour scale for the PET data. The CT im-
ages were viewed using soft tissue, lung and bone window image
levelling. More than one reader visually assessed PET, ceCT and
PET/CT images, and a consensus reached.
In the subset of patients who underwent PET/CT before and
after treatment onset, the transverse images of the ceCT examina-
tion before and after contrast enhancement were developed on
film. Two nuclear medicine physicians and two radiologists read
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the PET, co-registered PET/CT and ceCT images of each patient
in consensus. The anatomical location of FDG-avid lesions on
PET/CT images was directly compared with that on the ceCT im-
ages. Thus, the measurement of FDG concentrations and HU was
done for identical lesions. Images were assessed visually and in
addition the following parameters were measured: HU before and
at the first control, size of reference lesions, the distribution pat-
tern of FDG uptake and the visual intensity of FDG uptake before
and during treatment. The visual intensity of a lesion was classi-
fied as high, intermediate or low when, respectively, FDG uptake
was comparable to brain uptake, less than brain uptake but more
than uptake in normal liver tissue or not discernible from normal
soft tissue activity.
Response on ceCT was assessed according to the RECIST cri-
teria (response evaluation criteria in solid tumours) used for thera-
py monitoring of malignant diseases [13]. In the control examina-
tion a suspicious finding on ceCT was either a new lesion or an in-
crease in lesion size compared with previous examinations. FDG
uptake was measured in regions of interest (ROIs) drawn on the
PET image, and the mean value of the ROI was taken to calculate
standardised uptake values (SUVs). The ROI was defined on the
transverse slice of the corresponding CT image of the co-regis-
tered PET/CT scan where the lesion had the largest transverse 
diameter. The mean SUV was corrected for the body weight of the
patient. The same lesions were used as a reference to assess thera-
py response on ceCT images. All measurements were done by one
experienced physician using PMOD software (ED; PMOD Version
2.35; www.pmod.com).
On the PET images the treatment effect was measured according
to the recommendations of the EORTC PET study group [14]. Be-
cause in GIST tumours it is not uncommon to find several lesions, a
complete remission was defined as the disappearance of all FDG-
avid lesions. In addition to the SUV criterion defined by the EORTC
PET study group, we defined a partial response as a decrease in the
number of visible lesions with or without a decrease in FDG uptake
or a decrease in FDG uptake with or without a reduction in the num-
ber of lesions. Progression was defined as the appearance of new le-
sions or an increase in the SUV of the target lesion by >25%. Stable
disease was defined as an increase in FDG uptake of <25% or a de-
crease of <15% and a stable number of FDG-avid lesions [14]. If a
patient did not have visually increased uptake on the pre-treatment
PET and was still negative at the first control examination, the pa-
tient was categorised as having stable disease.
Subsequently a separate evaluation of the PET/CT and ceCT
scans was done before and after the introduction of treatment with
imatinib mesylate: two readers retrospectively assessed the ceCT
with the corresponding PET images of a patient and compared the
findings with the co-registered PET/CT images of the same patient.
Both examinations were read in consensus to evaluate the possible
advantage of PET/CT image co-registration over ceCT with sepa-
rate PET images for the anatomical delineation of active lesions.
Statistical evaluation
All values are given as mean ± standard deviation. The relative
decreases in FDG uptake and CT HU as measured in an ROI of
patients with either stable disease or partial or complete response
are given as percentage values. The time-to-event variables were
analysed with the log rank test and displayed on Kaplan-Meier
plots according to the imaging method used. The hazard ratios and
95% CI were estimated. Overall survival, time to progression and
time on medication with imatinib mesylate were calculated ac-
cording to the Kaplan-Meier method from the first day of treat-
ment. Survival comparisons were expressed using the log rank
test. All statistical analyses were done using the SPSS software,
version 10.0 for Mac.
Results
The imaging and clinical data of 34 consecutive patients
were available for this study (19 male, 15 female, mean
age 51.7±15.2 years, age range 21–76 years) (Table 1).
A total of 78 PET or PET/CT scans were acquired in
these patients for staging and restaging and during fol-
low-up. All patients except nos. 22, 26 and 27 underwent
one or several surgical interventions before the PET or
PET/CT examination (Table 1).
The median overall survival of the patients was 
44.5 months with a 2-year survival of 78% (95%
CI=63–94%). The median time on treatment with ima-
tinib mesylate was also 44.5 months, with 67% of 
patients still taking imatinib mesylate after 2 years 
(95% CI=49–85%). The median time to progression was
23.5 months (range 13.4–33.6 months), with a 2-year
progression-free survival of 49% (95% CI=28–69%).
Imaging findings of PET and PET/CT in 34 patients
FDG-avid lesions were found in the liver (n=16 patients;
one to seven lesions/patient) and the gastrointestinal tract
with or without extension into the mesentery or omentum
and the retroperitoneal soft tissues (n=20 patients; one to
five lesions/patient) (Table 1). An example of PET/CT
findings in a patient with abdominal GIST before treat-
ment (patient 10) is given in Fig. 1. Extra-abdominal tu-
mour involvement was found in mediastinal lymph
nodes, oesophagus, axillary lymph nodes, lung and bones
(n=4 patients; one to seven extra-abdominal lesions/pa-
tient) and confirmed by either endoscopy or fine-needle
aspiration with cytology (patients 3, 12 and 32; Fig. 2).
FDG PET identified more skeletal lesions than ceCT
images (in patients 14 and 32, involvement of a rib was
missed on ceCT). In seven patients no FDG-avid lesions
were found (patients 16, 17, 19, 21, 24, 33 and 34). In
patients 5 and 14, liver lesions were suspected on the CT
scan, but FDG uptake was not increased on the PET im-
ages (i.e. the uptake did not exceed physiological uptake
in the adjacent normal liver tissue); however, in the same
patients other liver lesions did show an increased FDG
uptake (Table 1). In patient 11, a lesion at the inferior
pole of the kidney was visible on the PET image, but
was believed to be a part of the urinary collecting sys-
tem. The combined information obtained using ceCT
with PET and co-registered PET/CT revealed the pres-
ence of the tumour. In patient 15, three pulmonary le-
sions each smaller than 5 mm were missed on the PET
images, but were correctly identified on the CT scan of
combined PET/CT.
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Impact on clinical decision-making
Indications for PET and PET/CT scanning were as fol-
lows: (a) for staging purposes, (b) to assess the effect,
shortly after the initiation of treatment, of imatinib mesy-
late in patients who had had a pre-treatment PET or
PET/CT scan, (c) to confirm a positive treatment effect
in patients with a reduction in tumour size on the routine
ceCT images during follow-up, (d) to confirm recurrent
disease in patients with suspicious findings on routine
ceCT images during follow-up, thus allowing adaptation
of the dosage of imatinib mesylate, (e) to control at an
early time point the efficacy of dosage adaptation in pa-
tients in whom dosage had been increased, (f) to control
at an early time point the efficacy of a lower dosage in
patients in whom dosage had been decreased, (g) to iden-
tify a (solitary) lesion with increased FDG uptake in a
patient with otherwise stable disease for the planning of
a selective surgical intervention and (h) to control the
success of a surgical intervention.
For the assessment of surgical operability, one patient
(no. 18) underwent PET scanning before salvage surgery.
The same patient underwent PET/CT scanning to evalu-
ate success of this intervention. Overall, three patients
initially considered as inoperable underwent surgery
with a curative intent after response to therapy with ima-
tinib mesylate (8% of patients, 4% of all PET scans). In
these three patients, PET and PET/CT information
served to correctly delineate the extension of a known 
lesion by virtue of its increased FDG uptake and to rule
out further lesions that might have been missed on the
ceCT images.
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Table 1. Patient characteristics
Patient Gender Age (yrs) Site of primary tumour Areas with suspicious FDG uptakeb
1 F 32 Small bowel Mesentery, retroperitoneum, pelvic mass
2 M 72 Stomach and omentum Stomach, omentum, caecum
3 F 72 Stomach Liver, pelvis, oesophagus
4 M 31 Stomach Liver, retroperitoneum, adrenal
5 M 50 Stomach Liver, retroperitoneum, upper abdomen
6 M 55 Small bowela Small bowel, pelvic mass
7 F 21 Small bowel Liver
8 M 63 Small bowela Liver
9 F 39 Retroperitoneum, upper abdomena Retroperitoneum, upper abdomen
10 F 58 Small bowel Stomach, small bowel, retroperitoneum
11 M 52 Small bowel, mesentery Stomach, small and large bowel, retroperitoneum
12 M 61 Small bowel Liver, axillary LN
13 M 46 Small bowel Small bowel, liver, retroperitoneum,
14 F 63 Small bowel, livera Liver, bone, axillary and mediastinal LN
15 M 76 Stomach Liver, mesentery
16 F 72 Small bowel, pelvic massa No
17 F 50 Small bowel No
18 M 71 Retroperitoneum, upper abdomena Liver, retroperitoneum, upper abdomen
19 M 60 Stomach No
20 F 67 Stomach Liver
21 M 67 Stomach No
22 F 21 Retroperitoneum, upper abdomena Liver, retroperitoneum
23 F 42 Small bowel Liver
24 M 44 Stomach No
25 M 65 Small bowel Small bowel, mesentery
26 F 31 Stomach Stomach, retroperitoneum
27 M 53 Rectum Rectum
28 F 59 Stomach Retroperitoneum, upper abdomen
29 M 58 Stomach Retroperitoneum, upper abdomen, mesentery
30 M 44 Stomach Liver
31 F 42 Stomach Liver, retroperitoneum, upper abdomen
32 F 30 Stomach Liver, mesentery small bowel, bone, LN behind the clavicle
33 M 47 Stomach No
34 M 43 Stomach No
LN lymph node
a The given location is probably the primary site
b
“No” indicates no increased FDG uptake visible at the time of
chronologically first PET or PET/CT scan, i.e. FDG uptake not
distinguishable from background activity or less than normal soft
tissue activity
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Comparison of PET/CT with PET and ceCT
In 15 of 34 patients a direct comparison of PET/CT find-
ings with PET and ceCT findings was done. Before the
start of therapy, 66 lesions were identified on the PET im-
ages of the PET/CT scan while 96 lesions were found on
the ceCT images, i.e. 45% more lesions were seen with
ceCT. The largest FDG-avid lesion ranged between 1 cm
and 20 cm (mean 5.0±6.2 cm, median 7.2 cm) as mea-
sured on the corresponding CT image. In six patients, de-
creased FDG uptake was observed in the centre of the le-
sion, compatible with central necrosis. In small lesions
the FDG uptake was usually strong and homogeneous,
but in large lesions the distribution of FDG was often het-
erogeneous, showing areas with strong, intermediate, low
or even no uptake (compatible with necrotic tissue).
The first follow-up ceCT examination in this sub-
group showed signs of partial response (n=6) or stable
disease (n=7) in 13 patients. In two patients, signs of
progressive disease were found despite treatment with
imatinib mesylate. The mean decrease in CT HU in the
target lesion between staging and first follow-up ceCT in
the six patients with a partial response was 39±22%
(range 14–74%). In the patients with stable disease, the
HU did not decrease. In contrast, on the corresponding
FDG PET images all patients showed complete remis-
sion (n=9), partial response (n=3) or stable disease
(n=3). In only four of 15 patients were concordant find-
Fig. 1. a Coronal maximum intensity projection image (MIP) and
transverse PET (top), CT (middle) and co-registered PET/CT im-
ages (bottom) of a 58-year-old female patient (patient 10) before
the introduction of treatment with imatinib mesylate. On the MIP
image, focal areas with increased FDG uptake are seen in the mid
abdomen (long arrow) and at the oesophago-gastric junction
(short arrow). An axillary lymph node is visible owing to parave-
nous tracer injection (asterisk). In the lower abdomen the appear-
ance of bowel uptake is not suggestive of tumour involvement. In
the transverse section at the level of the liver, no foci with in-
creased tracer uptake are visible, but the largest of the three hypo-
dense areas on the CT scan is also detectable on the FDG PET im-
age as an area with low FDG uptake (open arrows). b On the
transverse PET, CT and co-registered PET/CT images, areas with
increased FDG uptake and corresponding soft tissue mass are
present in the region of the duodenum, extending to the retroperi-
toneal soft tissues (large open white and black arrows), and at the
anterior wall of the peritoneal cavity (long white and black ar-
rows). There is a normal appearance of both kidneys and metal
clips are visible after previous surgical intervention (asterisk).
Within the large soft tissue mass in the duodenum only relatively
small foci took up FDG. c A focal site of FDG uptake was also
visible on the PET and PET/CT images at the level of the oe-
sophago-gastric junction (black arrows). This site corresponded to
a non-enlarged lymph node metastasis. On the ceCT scan (not
shown) and on the CT image of the PET/CT scan, this lymph node
was not delineated (black arrow)
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ings found on the first follow-up PET and ceCT, with 
either a partial response (patients 1 and 11) or stable 
disease (patients 13 and 15). The mean decrease in FDG
uptake in the target lesion in patients with stable disease
or a partial response was 55±20% (range 1–82%). How-
ever, in patients with several lesions the decrease in FDG
uptake in a target lesion did not necessarily reflect the
behaviour of other lesions.
The evaluation of the additional value of co-regis-
tered PET/CT images over PET images read together
with separate ceCT data revealed that in 25 of 30 exami-
nations at least one of the lesions was better delineated
on PET/CT images. In the other examinations PET with
ceCT was judged to be equal to co-registered PET/CT in
assessing the extent and size of a lesion. Furthermore,
the two readers found that exact delineation of FDG-avid
areas within large lesions would be useful to guide surgi-
cal procedures and to better assess operability.
Prognostic information obtained by PET and CT
In a subgroup of 28 patients (82%, 15 male, 13 female,
mean age 52±15 years, 21–76 years) a PET or PET/CT
Fig. 2. a Coronal MIP image and transverse PET (top), CT 
(middle) and co-registered PET/CT images (bottom) of a 72-year-
old female patient (patient 3) before the introduction of treatment
with imatinib mesylate. A large FDG-avid and hypodense lesion is
present in the liver, involving both lobes (white open arrows).
FDG uptake in this large lesion is not homogeneous. On the MIP
image a large lesion adjacent to the heart, which did not take up
FDG, is visible (long black arrow). Smaller foci of increased 
tracer uptake are present in the middle and lower abdomen (small
black arrows). b The lesion at the distal oesophagus shows intense
FDG uptake (patient after total gastrectomy and splenectomy). 
c In the mid-abdomen and pelvis, several lesions were found cor-
responding to mesenteric lymph node involvement (white arrows)
and uptake in the wall of non-enlarged bowel loops (white and
black open arrows). The discrimination of such uptake from non-
specific muscular FDG uptake is difficult. d Seven weeks after the
beginning of treatment a control scan was obtained, showing com-
plete remission on the PET image and partial remission on the
ceCT scan (not shown). On the CT image of the PET/CT scan, the
liver lesion was less dense than on the first scan, but had not
shrunk
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scan performed after the start of treatment was available,
at a median interval of 19 days (range 11–111 days). The
median overall survival of the 28 patients undergoing
PET or PET/CT scanning after the start of imatinib me-
sylate treatment was 44.5 months, with a 2-year survival
of 80% (95% CI=67–92%), indicating that this subgroup
is comparable to the whole patient population. In 20 out
of 28 patients a PET/CT scan was performed before and
after treatment onset and, therefore, the response to ima-
tinib mesylate treatment was measurable in these pa-
tients using both PET and CT criteria.
In the 28 patients in whom examinations were per-
formed after treatment onset, the status of image criteria
in the first follow-up examination and the change in PET
and CT criteria between the pre-treatment and the first
follow-up scan were used to compare the prognostic
power of PET and CT. A post-treatment PET scan with-
out pathological FDG accumulation was predictive of
significantly better overall survival and longer time to
progression compared with a follow-up PET image with
FDG-avid areas (p=0.001 and 0.002, Figs. 3, 4). In con-
trast, CT findings were not suitable for prediction of
overall survival or the time to progression, because in
only two patients was the first follow-up CT scan con-
sidered to be normal (p=0.469 and 0.030; log rank test
p=0.706). The measurement of changes between pre-
Fig. 3. Overall patient survival
according to the result of the
first PET or PET/CT scan after
treatment onset. Vertical axis,
% of patients; horizontal axis,
time. A Patients without suspi-
cious FDG uptake on the image
(n=16): the median survival
was not reached. Mean 2-year
survival was 100%. B Patients
with suspicious FDG uptake on
the image (n=12): the median
survival was 22 months (range
9.1–38.5). Mean 2-year sur-
vival was 49% (range 20–52).
There was a significant differ-
ence between these two patient
groups (log rank test p=0.001)
Fig. 4. Time to progression ac-
cording to the result of the first
post-treatment PET or PET/CT
scan. Vertical axis, % of pa-
tients; horizontal axis, time.
A Patients without suspicious
findings on the PET image
(n=15): the median time to pro-
gression was 32.2 months
(range 23.1–41.3). The 2-year
time to progression was 65%
(range 41–90). B Patients with
suspicious findings on the PET
image (n=9): the median time
to progression was 9.3 months
(range 0–24.7). The 2-year
time to progression was 22%
(range 5–49). There was a sig-
nificant difference between
these two patient groups (log
rank test p=0.002)
treatment PET and first follow-up PET examination and
between pre-treatment CT and first follow-up CT exami-
nation revealed a significant power of PET information
in predicting the overall survival for responders (PET
changes: log rank test p=0.009; CT changes: log rank
test p=0.706). Measurement of changes between the pre-
treatment PET scan and the first follow-up PET exami-
nation was not suitable for discrimination of the time to
progression in responders and non-responders (log rank
test p=0.129). This was due to the inclusion of patients
with FDG-negative scans before treatment onset in our
evaluation: in such patients it was not possible to mea-
sure a decrease in FDG uptake between pre-treatment
and post-treatment scans. Based on the CT criteria,
again, no significant difference was observed for the
time to progression between patients with and patients
without a measurable change between the scans (log
rank test p=0.100).
Discussion
The results of this study confirm previous reports show-
ing a decrease in FDG uptake shortly after the introduc-
tion of treatment with imatinib mesylate [8–10]. We con-
firm other authors’ findings that patients responding to
treatment, as measured by normalisation of FDG-avid ar-
eas, have a better clinical outcome than patients in whom
FDG uptake is still present [8–10]. In contrast to the
short follow-up in previous reports, our patients have
been followed up for a median of more than 3 years, and
the minimum follow-up of the patients who are still alive
is 22 months. Furthermore, in our study all PET exami-
nations were considered, while in the study of Stroobants
et al. patients with low FDG uptake at baseline were ex-
cluded [10]. In patients with negative PET scans before
treatment onset, but with clinical evidence of active dis-
ease, comparative measurement of FDG activity between
a pre-treatment and a post-treatment scan seems futile.
However, our data suggest that a single post-treatment
PET scan can provide prognostic information on overall
survival and the time to progression, while a single post-
treatment ceCT examination is not useful for this pur-
pose.
More tumour lesions were found on ceCT images
than on PET images. This may indicate that PET alone is
insufficient to identify and characterise GIST lesions
when surgery is intended. However, based on the long-
term follow-up in our patients, it seems that FDG-avid
lesions are clinically more important than lesions identi-
fied on ceCT images and CT images of the PET/CT
scan, since they determine further management and clini-
cal outcome. CT findings often remain equivocal in pa-
tients who have previously undergone surgery and who
will show residual non-specific postoperative changes.
Additionally, in most patients many lesions identified by
CT cannot be confirmed histologically. Therefore, it is
possible that reliance solely on the structural image in-
formation derived from ceCT will lead to false positive
findings.
We found a broad spectrum of FDG uptake in the le-
sions. In large lesions a centrally decreased uptake was
often seen, compatible with a necrotic area within the
tumour. Furthermore, it was possible to find lesions
with very high, moderate or no uptake at all in the same 
patient. This could have been due to the origination of
lesions from different cell clones. GIST lesions can be
missed on PET images, when pathological FDG uptake
in a tumour cannot be discriminated from physiological
uptake in the surrounding normal soft tissues. It is im-
portant to note that small FDG-avid lesions may be
missed owing to the limited spatial resolution of the
PET camera. Insufficient FDG uptake could have been
the reason for the negative baseline PET in patient 21
with clinically active GIST. This patient was successful-
ly treated with imatinib mesylate and remained FDG
negative at two follow-up PET studies. This finding
suggests that patients with clinically active disease may
show no FDG-avid lesions before treatment onset, but
nevertheless should be candidates for imatinib mesylate
therapy.
Our data further suggest that co-registered PET/CT
images facilitate the correct anatomical delineation of
FDG uptake compared with the combination of separate
ceCT and PET images. The examples in Figs. 1 and 2 
illustrate how areas of increased FDG uptake can easily
be co-registered to the anatomical structure as seen on
CT images. In such cases the accuracy of PET/CT-based
image co-registration could facilitate the identification of
the optimal biopsy site and improve the planning of sur-
gical procedures. In patients with equivocal ceCT find-
ings after surgery, PET could identify active residual dis-
ease. Although to date it is not clear whether FDG-avid
and non-avid areas differ in respect of histological prop-
erties, our data clearly suggest that information on FDG
avidity has a clinical impact on further treatment 
decisions. Since FDG uptake in a lesion may reflect met-
abolic or even mitotic activity in GIST tumours, future
studies should assess whether FDG uptake could serve as
a direct measure of the aggressiveness of the tumour as
defined by mitotic count [15]. Previous work has shown
that FDG uptake is correlated with the amount of malig-
nant cells or the aggressiveness of solid tumours [16,
17]. The assessment of operability is important since sur-
gery with complete resection is the only curative therapy,
and the prognosis of a patient with GIST (with low ma-
lignant potential) is excellent after complete resection
[18]. Successful complete surgical resection is also im-
portant for the control of local recurrence or concomitant
and metastatic disease [19]. Furthermore, it has recently
been suggested that treatment with imatinib mesylate
may improve the surgical outcome in patients with resid-
ual GIST tumour[20]. Therefore, in our patients many
follow-up examinations were done to assess operability,
160
European Journal of Nuclear Medicine and Molecular Imaging Vol. 32, No. 2, February 2005
and in three patients surgery was performed after
PET/CT imaging. We found that the assessment of oper-
ability in GIST patients is facilitated by PET/CT. How-
ever, the clinical relevance of better anatomical delin-
eation of FDG uptake remains to be demonstrated in 
future studies. Additionally, future studies will have to
define clinical parameters suitable for indicating when
follow-up examinations with PET or PET/CT should 
be performed and to determine whether routine control
examinations at predefined time intervals are suitable for
follow-up.
From a clinical point of view, stable disease under
imatinib mesylate therapy signifies treatment success. 
In contrast, using RECIST and EORTC criteria for the
assessment of CT and PET images only a measurable
improvement, such as a decrease in lesion size or FDG
uptake, is considered a response and indicative of suc-
cessful therapy. We found it difficult to apply these im-
aging criteria to our GIST patients. If, for example, FDG
uptake appeared in new lesions during follow-up while
disappearing in old lesions, such a finding was still con-
sidered to indicate stable disease as long as the FDG up-
take in the reference lesion remained stable. Because a
single GIST patient can have many lesions, a lesion-
based evaluation and direct comparison with CT images
becomes utterly impossible. Therefore, the development
of parameters which are easily applicable in routine 
imaging should improve the assessment of PET and
PET/CT studies in this patient group.
In summary, the results of this study suggest that
PET and PET/CT scanning have high prognostic rele-
vance and yield clinically relevant information for treat-
ment planning in GIST patients. This study also sug-
gests that the use of a single post-treatment PET scan to
identify the presence of FDG uptake is sufficient for the
prediction of patient outcome and that a pre-treatment
scan is not needed to predict overall survival. Patients
not showing a response on a PET scan days to weeks af-
ter the start of treatment carry a worse prognosis and al-
ternative treatment strategies should be considered. PET
is essential to early treatment response assessment and
CT imaging is needed to plan surgical interventions.
These complementary methods are integrated in PET/
CT, which was found to provide additional information
compared with evaluation of separate PET and ceCT
images.
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